Using the Past to Maximize the Success Probability of Future Anti-Viral Vaccines

Overview

Journal Vaccines (Basel)

Date 2020 Oct 6

PMID 33019507

Authors

Philip Serwer

Affiliations

Soon will be listed here.

Abstract

Rapid obtaining of safe, effective, anti-viral vaccines has recently risen to the top of the international agenda. To maximize the success probability of future anti-viral vaccines, the anti-viral vaccines successful in the past are summarized here by virus type and vaccine type. The primary focus is on viruses with both single-stranded RNA genomes and a membrane envelope, given the pandemic past of influenza viruses and coronaviruses. The following conclusion is reached, assuming that success of future strategies is positively correlated with strategies successful in the past. The primary strategy, especially for emerging pandemic viruses, should be development of vaccine antigens that are live-attenuated viruses; the secondary strategy should be development of vaccine antigens that are inactivated virus particles. Support for this conclusion comes from the complexity of immune systems. These conclusions imply the need for a revision in current strategic planning.

References

McCarthy P, Sharyan A, Sheikhi Moghaddam L . Meningococcal Vaccines: Current Status and Emerging Strategies. Vaccines (Basel). 2018; 6(1). PMC: 5874653. DOI: 10.3390/vaccines6010012. View

Plotkin S . History of vaccination. Proc Natl Acad Sci U S A. 2014; 111(34):12283-7. PMC: 4151719. DOI: 10.1073/pnas.1400472111. View

Hyakumura M, Walsh R, Thaysen-Andersen M, Kingston N, La M, Lu L . Modification of Asparagine-Linked Glycan Density for the Design of Hepatitis B Virus Virus-Like Particles with Enhanced Immunogenicity. J Virol. 2015; 89(22):11312-22. PMC: 4645671. DOI: 10.1128/JVI.01123-15. View

Joe C, Chatterjee S, Lovrecz G, Adams T, Thaysen-Andersen M, Walsh R . Glycoengineered hepatitis B virus-like particles with enhanced immunogenicity. Vaccine. 2020; 38(22):3892-3901. DOI: 10.1016/j.vaccine.2020.03.007. View

HILLEMAN M . Current overview of the pathogenesis and prophylaxis of measles with focus on practical implications. Vaccine. 2001; 20(5-6):651-65. DOI: 10.1016/s0264-410x(01)00384-x. View

Houser K, Subbarao K . Influenza vaccines: challenges and solutions. Cell Host Microbe. 2015; 17(3):295-300. PMC: 4362519. DOI: 10.1016/j.chom.2015.02.012. View

Arisaka F, Yap M, Kanamaru S, Rossmann M . Molecular assembly and structure of the bacteriophage T4 tail. Biophys Rev. 2017; 8(4):385-396. PMC: 5418481. DOI: 10.1007/s12551-016-0230-x. View

Serwer P . Optimizing Anti-Viral Vaccine Responses: Input from a Non-Specialist. Antibiotics (Basel). 2020; 9(5). PMC: 7277631. DOI: 10.3390/antibiotics9050255. View

Thisyakorn U, Thisyakorn C . Latest developments and future directions in dengue vaccines. Ther Adv Vaccines. 2014; 2(1):3-9. PMC: 3991153. DOI: 10.1177/2051013613507862. View

10.

Bravo C, Mege L, Vigne C, Thollot Y . Clinical experience with the inactivated hepatitis A vaccine, Avaxim 80U Pediatric. Expert Rev Vaccines. 2019; 18(3):209-223. DOI: 10.1080/14760584.2019.1580578. View

11.

Javaid N, Yasmeen F, Choi S . Toll-Like Receptors and Relevant Emerging Therapeutics with Reference to Delivery Methods. Pharmaceutics. 2019; 11(9). PMC: 6781272. DOI: 10.3390/pharmaceutics11090441. View

12.

Gotuzzo E, Yactayo S, Cordova E . Efficacy and duration of immunity after yellow fever vaccination: systematic review on the need for a booster every 10 years. Am J Trop Med Hyg. 2013; 89(3):434-44. PMC: 3771278. DOI: 10.4269/ajtmh.13-0264. View

13.

Novoa R, Calderita G, Arranz R, Fontana J, Granzow H, Risco C . Virus factories: associations of cell organelles for viral replication and morphogenesis. Biol Cell. 2005; 97(2):147-72. PMC: 7161905. DOI: 10.1042/BC20040058. View

14.

Maple P . Application of Oral Fluid Assays in Support of Mumps, Rubella and Varicella Control Programs. Vaccines (Basel). 2015; 3(4):988-1003. PMC: 4693228. DOI: 10.3390/vaccines3040988. View

15.

Izmirly A, Alturki S, Alturki S, Connors J, Haddad E . Challenges in Dengue Vaccines Development: Pre-existing Infections and Cross-Reactivity. Front Immunol. 2020; 11:1055. PMC: 7325873. DOI: 10.3389/fimmu.2020.01055. View

16.

Schuster B, Sleytr U . Relevance of glycosylation of S-layer proteins for cell surface properties. Acta Biomater. 2015; 19:149-157. PMC: 4414373. DOI: 10.1016/j.actbio.2015.03.020. View

17.

Richardson V, Hernandez-Pichardo J, Quintanar-Solares M, Esparza-Aguilar M, Johnson B, Gomez-Altamirano C . Effect of rotavirus vaccination on death from childhood diarrhea in Mexico. N Engl J Med. 2010; 362(4):299-305. DOI: 10.1056/NEJMoa0905211. View

18.

Filgueira L, Lannes N . Review of Emerging Japanese Encephalitis Virus: New Aspects and Concepts about Entry into the Brain and Inter-Cellular Spreading. Pathogens. 2019; 8(3). PMC: 6789543. DOI: 10.3390/pathogens8030111. View

19.

Dudas R, Karron R . Respiratory syncytial virus vaccines. Clin Microbiol Rev. 1998; 11(3):430-9. PMC: 88889. DOI: 10.1128/CMR.11.3.430. View

20.

Shi L, Sings H, Bryan J, Wang B, Wang Y, Mach H . GARDASIL: prophylactic human papillomavirus vaccine development--from bench top to bed-side. Clin Pharmacol Ther. 2007; 81(2):259-64. DOI: 10.1038/sj.clpt.6100055. View